Skip to content

Michelle Priest

3 papers in the library · 5 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.

Rand health quarterly June 1, 2026 Michelle Priest, Beau Kilmer, Ben Senator et al.

An increasing number of U.S. states are implementing or considering alternative policies to the prohibition of some psychedelic substances for nonclinical purposes. The authors present new data and analysis to inform these discussions with survey results on the use of 11 psychedelic substances and detailed information about the prevalence of microdosing (i.e., taking a fraction of a full dose,...

Psilocybin microdosing in the United States: Insights from a nationally representative survey

Addiction March 8, 2026 Michelle Priest, Beau Kilmer, Rajeev Ramchand et al. 1 citation

At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to report microdosing the last time they used than those who have used psilocybin more than one year ago; however, approximately 15% respondents who used psilocybin in their lifetime were unsure whether they microdosed the last time they used....

Considering Alternatives to Psychedelic Drug Prohibition

RAND Corporation eBooks 2024 Beau Kilmer, Michelle Priest, Rajeev Ramchand et al. 4 citations

Psychedelic substances, such as psilocybin and LSD, have long been touted as holding promise for treating some mental health conditions. An increasing number of U.S. state and local governments are implementing or considering alternative policies to prohibiting some of these substances for nonclinical purposes (i.e., adults can use them for any reason). The authors of this report present new...